Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
Paton NI, Stöhr W, Arenas-Pinto A, Clarke A, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Sanders K, Dunn DT; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team. Paton NI, et al. Among authors: dunn dt. EClinicalMedicine. 2024 Feb 10;69:102457. doi: 10.1016/j.eclinm.2024.102457. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361989 Free PMC article.
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.
Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees. Barber TJ, et al. J Antimicrob Chemother. 2012 Apr;67(4):995-1000. doi: 10.1093/jac/dkr569. Epub 2012 Jan 17. J Antimicrob Chemother. 2012. PMID: 22258921
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.
El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database; (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees; UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees. El Bouzidi K, et al. Among authors: dunn dt. J Antimicrob Chemother. 2016 Dec;71(12):3487-3494. doi: 10.1093/jac/dkw343. Epub 2016 Sep 28. J Antimicrob Chemother. 2016. PMID: 27856703 Free PMC article.
A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators.
Dunn DT, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, McCormack S, Babiker AG, Darbyshire JH; Evaluation of Resistance Assays (ERA) Trial Investigators. Dunn DT, et al. J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):553-9. doi: 10.1097/01.qai.0000148533.12329.96. J Acquir Immune Defic Syndr. 2005. PMID: 15793365 Clinical Trial.
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study Steering Committee. Barber TJ, et al. Antivir Ther. 2011;16(6):805-14. doi: 10.3851/IMP1818. Antivir Ther. 2011. PMID: 21900712
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Steering Committee. O'Connor JL, et al. AIDS. 2014 Mar 27;28(6):919-24. doi: 10.1097/QAD.0000000000000165. AIDS. 2014. PMID: 24335482
Factors influencing lopinavir and atazanavir plasma concentration.
Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; UK CHIC Steering Committee. Stöhr W, et al. J Antimicrob Chemother. 2010 Jan;65(1):129-37. doi: 10.1093/jac/dkp408. J Antimicrob Chemother. 2010. PMID: 19897506 Free PMC article.
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D; UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC). Harrison L, et al. AIDS. 2010 Jul 31;24(12):1917-22. doi: 10.1097/QAD.0b013e32833c1d93. AIDS. 2010. PMID: 20588166
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Phillips AN, et al. AIDS. 2005 Mar 25;19(5):487-94. doi: 10.1097/01.aids.0000162337.58557.3d. AIDS. 2005. PMID: 15764854
148 results